Claims for Patent: 9,174,975

Summary for Patent: 9,174,975

Title:	Remedy for integration dysfunction syndrome
Abstract:	The present invention provides a novel method for treatment of schizophrenia which can improve wide-ranging symptoms of schizophrenia, especially positive symptoms and negative symptoms without being accompanied by extrapyramidal symptoms, which comprises orally administering as an active compound (1R,2S,3R,4S)--N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-piperazinylme- thyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide or a pharmaceutically acceptable salt thereof (e.g., hydrochloride) at a daily dose of 5 mg to 120 mg once a day to a patient with schizophrenia, and a therapeutic agent to be used in the method.
Inventor(s):	Nakamura; Mitsutaka (Osaka, JP), Ogasa; Masaaki (Osaka, JP), Sami; Shunsuke (Osaka, JP)
Assignee:	SUMITOMO DAINIPPON PHARMA CO., LTD (Osaka, JP)
Application Number:	10/525,021
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,174,975
Patent Claims:	1. A method for treating the negative symptoms of schizophrenia and/or the cognitive dysfunction of schizophrenia in a patient, which comprises orally administering a once daily dose of 5 mg to 120 mg of the active compound: (1R,2S,3R,4S)--N[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-pipe- razinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide of the formula (1): ##STR00005## or a pharmaceutically acceptable salt thereof to a patient suffering from negative symptoms of schizophrenia and/or cognitive dysfunction of schizophrenia. 2. The method of claim 1, which is a method for treating the negative symptoms of schizophrenia in a patient. 3. The method of claim 1, which is a method for treating the cognitive dysfunction of schizophrenia in a patient. 4. The method of claim 1, 2 or 3 wherein the pharmaceutically acceptable salt of said active compound is (1R,2S,3R,4S)--N-[(1R,2R)-2-[4-(1,2benzoisothiazol-3-yl)-1-piperazinylmet- hyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide hydrochloride. 5. The method of any one of claims 1, 4, 2 and 3, wherein a once daily dose of 20 mg to 80 mg of said active compound or a pharmaceutically acceptable salt thereof is administered to said patient. 6. The method of any one of claims 1, 4, 2 and 3, wherein said patient is in a chronic stage of schizophrenia, and wherein a once daily dose of 5 mg to 80 mg of said active compound or a pharmaceutically acceptable salt thereof is administered to said patient. 7. The method of any one of claims 1, 4, 2 and 3, wherein said patient is in an acute stage of schizophrenia, and wherein a once daily dose of 40 mg to 120 mg of said active compound or a pharmaceutically acceptable salt thereof is administered to said patient. 8. The method of any one of claims 1, 4, 2 and 3, wherein a once daily dose of 40 mg of said active compound or a pharmaceutically acceptable salt thereof is administered to said patient. 9. The method of any one of claims 1, 4, 2 and 3, wherein a once daily dose of 80 mg of said active compound or a pharmaceutically acceptable salt thereof is administered to said patient. 10. The method of any one of claims 1, 4, 2 and 3, wherein a once daily dose of 120 mg of said active compound or a pharmaceutically acceptable salt thereof is administered to said patient. 11. The method of claim 6, wherein a once daily dose of 10 mg to 80 mg of said active compound or a pharmaceutically acceptable salt thereof is administered to said patient.